Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553306 · ClinicalTrials.gov registry record · Phase 1
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00553306 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00553306, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different ways and stop tumor cells from growing. Giving laboratory-treated T cells together with aldesleukin after cyclophosphamide may be an effective treatment for melanoma. PURPOSE: This phase I/II trial is studying the side effects of giving laboratory-treated T cells together with aldesleukin after cyclophosphamide and to see how well they work in treating patients with stage IV melanoma.
Interventions
- DRUG cyclophosphamide
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553306
The ClinicalTrials.gov registry entry for NCT00553306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00553306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00553306 about?
NCT00553306 is a clinical study titled "Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma". RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different ways and stop tumor cells from growing. Giving laboratory-treated T cells together with aldesleukin after cyclopho...
What is the current status of trial NCT00553306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00553306?
The interventions under investigation include: cyclophosphamide (DRUG), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00553306?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.